InSilico Medicine (HKG:3696) will be included as a constituent stock of the Hang Seng Biotech Index effective the close of market on June 5, according to a Tuesday Hong Kong bourse filing.
The AI-driven drug discovery firm believes the inclusion reflects the capital market's recognition of its long-term growth potential.